On the contrary, mutations of ARID1A, which belongs to the ARID1 family member, might be associated with a different outcome among patients received ICIs treatment and participate to the improved ICIs outcome in NSCLC via associating KRAS mutations as reported by Gandara D, et al. Besides, Goswami S, et al. confirmed that ARID1A mutations plus CXCL13 expression as combinatorial biomarkers to predict the sensitive phenotype to ICIs in metastatic urothelial carcinoma (Goswami et al. 2020). Here, KRAS is linked to non-small cell lung carcinoma.